Bifidobacterium animalis Probio-M8 improves sarcopenia physical performance by mitigating creatine restrictions imposed by microbial metabolites

NPJ Biofilms Microbiomes. 2024 Dec 5;10(1):144. doi: 10.1038/s41522-024-00618-1.

Abstract

Sarcopenia is a major health challenge due to an aging population. Probiotics may improve muscle function through gut-muscle axis, but their efficacy and mechanisms in treating sarcopenia remain unclear. This study investigated the impact of Bifidobacterium animalis subsp. lactis Probio-M8 (Probio-M8) on old mice and sarcopenia patients. We analyzed 43 subjects, including gut microbiome, fecal metabolome, and serum metabolome, using a multi-omics approach to assess whether Probio-M8 can improve sarcopenia by modulating gut microbial metabolites. Probio-M8 significantly improved muscle function in aged mice and enhanced physical performance in sarcopenia patients. It reduced pathogenic gut species and increased beneficial metabolites such as indole-3-lactic acid, acetoacetic acid, and creatine. Mediating effect analyses revealed that Probio-M8 effectively reduced n-dodecanoyl-L-homoserine lactone level in gut concurrent with increased creatine circulation, to significantly enhance host physical properties. These findings provide new insights into probiotics as a potential treatment for sarcopenia by modulating gut microbiota metabolism.

MeSH terms

  • Aged
  • Animals
  • Bifidobacterium animalis*
  • Creatine*
  • Feces* / chemistry
  • Feces* / microbiology
  • Female
  • Gastrointestinal Microbiome*
  • Humans
  • Indoles
  • Male
  • Metabolome
  • Mice
  • Mice, Inbred C57BL
  • Physical Functional Performance
  • Probiotics* / administration & dosage
  • Sarcopenia* / metabolism

Substances

  • Creatine
  • indole-3-lactic acid
  • Indoles